Open AccessSodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Author(s) -
Tim Hropot,
Tadej Battelino,
Klemen Dovc
Publication year - 2022
Publication title -
hormone research in paediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.816
H-Index - 89
eISSN - 1663-2826
pISSN - 1663-2818
DOI - 10.1159/000527653
Subject(s) - type 2 diabetes , medicine , renal glucose reabsorption , diabetes mellitus , insulin , clinical trial , endocrinology , placebo , pharmacology , alternative medicine , pathology
With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are glucose-lowering agents that inhibit the reabsorption of filtered glucose in the kidneys, thus promoting glucosuria. Because the glucose-lowering effect of SGLT2 inhibitors is achieved independently of insulin secretion, it has been speculated whether they could bridge the gap towards achieving glycaemic targets in individuals with type 1 diabetes.